Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Upcoming Events
Archived Events
21st Annual Needham Virtual Healthcare Conference
April 11, 2022 at 2:15 PM EDT
2nd Guggenheim Targeted Protein Degradation Day
March 16, 2022 at 11:00 AM EDT
32nd Annual Oppenheimer Healthcare Conference
March 15, 2022 at 4:00 PM EDT
11th Annual SVB Leerink Global Healthcare Conference
February 17, 2022 at 3:40 PM EST
Discussion of Initial NX-2127 Phase 1a PK/ PD Data
October 27, 2021 at 8:30 AM EDT